|Videos|January 24, 2022
SABCS 2021: Brain Metastases Updates in Breast Cancer
Focusing on datasets from the SABCS 2021 Virtual Meeting, panelists consider novel approaches to the management of brain metastases in breast cancer.
Advertisement
Data from the following clinical trials are discussed:
- PD4-02: Safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis in HER2+ breast cancer: Results from TBCRC049, a phase 2 nonrandomized study
- PD4-04: Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB)
- P1-18-26: Intracranial efficacy of tucatinib, palbociclib, and letrozole combination in patients with HR+/HER2+ breast cancer and brain metastases
- P1-21-03: Efficacy of tyrosine kinase inhibitors (TKIs) in the treatment of patients with HER2+ breast cancer with or without brain metastases: a systematic review and meta-analysis
- OT1-13-01: HER2CLIMB-04: phase 2 trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases
Advertisement
Related to this article
Nunnery and Bond discuss how patients and advocates can navigate second opinions, mental health support, and the long-term effects of cancer treatment.
Invikafusp alfa now holds fast track status across TMB-H solid tumors that progressed after prior therapy, including checkpoint inhibition.
Matthew P. Goetz, MD, explores menopausal status, recurrence risk, and adjuvant CDK4/6 inhibitor selection in HR-positive breast cancer.
Matthew P. Goetz, MD, explores first-line treatment selection, emerging targeted therapies, and unmet sequencing needs in metastatic breast cancer.
Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ESMO 2026.
The top 5 OncLive TV videos of the week.
The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
VOLGA, DASL-HiCaP Data Highlight Key Genitourinary Cancer Presentations Arriving at ESMO 2026
2
Stay Ahead of ESMO 2026: See What Lung Cancer Experts Are Prioritizing
3
CHMP Recommends Approval of Daraxonrasib for Previously Treated Metastatic Pancreatic Cancer
4
Lifileucel Linked to Low Rates of Post-Discharge Severe TRAEs, Readmissions in Advanced Melanoma
5